SESSION TITLE: Lung Cancer III
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Lung Cancer continues to be the leading cause of cancer related mortality worldwide. Advances in molecular technology have enabled in-depth molecular profiling of cancer. Molecularly targeted therapies have dramatically improved treatment for patients whose tumors harbor somatically activated oncogenes such as mutant EGFR or translocated ALK, RET, or ROS1. Somatic mutation and genomic rearrangements occur at a high rate in lung cancer; therefore, precise identification of frequent driver gene alteration becomes a difficult task. Moreover, multiple environmental factors influence the presentations of lung cancer; therefore, detection of mutation profile in our target population is essential in order to recommend appropriate treatment approach in individual patients. In this study, we determine the frequency of mutations that are targetable for therapy in lung cancer in our population.